Abnormal Platelet Aggregation Studies
Acquired causes of platelet dysfunction:
Ingestion of aspirin or aspirin-like compounds or NSAIDs
Impaired renal function
Exposure to cardiopulmonary bypass
Presence of a paraprotein
Congenital causes of platelet dysfunction:
Storage pool disease
Disorders of thromboxane production or action
Suggested Additional Lab Testing
Platelet aggregation studies with characteristic response patterns for the different agonists help identify Glanzmann thrombasthenia, Bernard-Soulier disease, aspirin ingestion, and defects in thromboxane production or action.
Plasma or serum BUN and creatinine and urinalysis to assess renal function should be ordered.
If aspirin ingestion is suspected but denied by patient, measurement of salicylates (metabolites of aspirin) may prove useful.
Bone marrow biopsy may be useful if myeloproliferative disease is suspected.
Serum protein electrophoresis can reveal a paraprotein. To identify platelet granule storage pool disease, assays for the granular contents of platelets can be performed, but these are complex, costly, and rarely performed.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Axillary Node Management for Breast Cancer: Is Less More?
- Breast Cancer: Foregoing Axillary Dissection May Not Affect Long-term Survival
- Non-steroidal Anti-inflammatory Drugs May Improve Survival in Kidney Cancer
- High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML
- Potentially Inappropriate Medications May Shorten Survival Among Elderly Patients With Lymphoma
- Colorectal Cancer Screening: Utility of Septin-9 Assays
- Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC
- Phase 2 Study of Nivolumab Plus Ipilimumab for Gastric, Ovarian, and Breast Cancer
- Phase 1 Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
- Priming Lung Cancer To Respond to Immunotherapy: Findings and Current Research